Expert Ratings for Adaptive Biotechnologies
Portfolio Pulse from Benzinga Insights
Adaptive Biotechnologies (NASDAQ:ADPT) has received mixed ratings from analysts in the last quarter, with 2 somewhat bullish and 2 indifferent ratings. The company's average 12-month price target is $12.5, representing a 10.71% decrease from the previous average price target of $14.00.
October 24, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Adaptive Biotechnologies has received mixed ratings from analysts, with a lower average price target.
The mixed ratings from analysts and the decrease in the average price target could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100